Patents by Inventor Anjali Kumar
Anjali Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124440Abstract: Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.Type: ApplicationFiled: December 16, 2021Publication date: April 18, 2024Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Swapan Kumar SAMANTA, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
-
Patent number: 10624905Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 27, 2018Date of Patent: April 21, 2020Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20180311260Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 27, 2018Publication date: November 1, 2018Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 9949987Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 15, 2017Date of Patent: April 24, 2018Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20170182068Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 15, 2017Publication date: June 29, 2017Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20170135957Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 9555047Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: August 18, 2014Date of Patent: January 31, 2017Assignee: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 9555048Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: August 18, 2014Date of Patent: January 31, 2017Assignee: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20150025050Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: August 18, 2014Publication date: January 22, 2015Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140356437Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 8828440Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 16, 2012Date of Patent: September 9, 2014Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140242170Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: December 16, 2013Publication date: August 28, 2014Applicant: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20120288534Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 16, 2012Publication date: November 15, 2012Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20120282298Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: February 8, 2012Publication date: November 8, 2012Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20100273868Abstract: The invention pertains to a method of treating a condition mediated by or characterized by increased 5-lipoxygenase activity like for instance asthma in a patient suffering therefrom comprising administering to said patient a composition comprising (R)-zileuton and a pharmaceutically acceptable excipient, wherein said composition is substantially free of (S)-zileuton.Type: ApplicationFiled: January 4, 2008Publication date: October 28, 2010Inventors: Walter Newman, Anjali Kumar, Lynne Libertine
-
Publication number: 20040086519Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.Type: ApplicationFiled: May 7, 2003Publication date: May 6, 2004Applicants: Genetics Institute, LLC, Montreal Heart Institute of MontrealInventors: Anjali Kumar, Robert G. Schaub, Jean-Francois Tanguay, Yahye Merhi